Exhibit 8
Dr. Reddy’s Laboratories Limited
Subsidiary companies
As of March 31, 2011
Subsidiary companies
As of March 31, 2011
Country of | Percentage of Direct/ | |||||
Name of Subsidiary | Incorporation | Indirect Ownership Interest | ||||
DRL Investments Limited | India | 100 | % | |||
Reddy Pharmaceuticals Hong Kong Limited | Hong Kong | 100 | % | |||
OOO JV Reddy Biomed Limited | Russia | 100 | % | |||
Reddy Antilles N.V. | Netherlands | 100 | % | |||
Reddy Netherlands B.V. | Netherlands | 100 | %(1) | |||
Reddy US Therapeutics, Inc. | U.S.A. | 100 | %(1) | |||
Dr. Reddy’s Laboratories, Inc. | U.S.A. | 100 | %(10) | |||
Dr. Reddy’s Farmaceutica do Brasil Ltda | Brazil | 100 | % | |||
Cheminor Investments Limited | India | 100 | % | |||
Aurigene Discovery Technologies Limited | India | 100 | % | |||
Aurigene Discovery Technologies, Inc. | U.S.A. | 100 | %(3) | |||
Kunshan Rotam Reddy Pharmaceutical Co. Limited | China | 51.33 | %(4) | |||
Dr. Reddy’s Laboratories (EU) Limited | United Kingdom | 100 | %(10) | |||
Dr. Reddy’s Laboratories (U.K.) Limited | United Kingdom | 100 | %(5) | |||
Dr. Reddy’s Laboratories (Proprietary) Limited | South Africa | 100 | %(12) | |||
Reddy Cheminor S.A. | France | 100 | %(2) | |||
OOO Dr. Reddy’s Laboratories Limited | Russia | 100 | % | |||
Dr. Reddy’s Bio-sciences Limited | India | 100 | % | |||
Promius Pharma LLC (formerly Reddy Pharmaceuticals, LLC) | U.S.A. | 100 | %(6) | |||
Trigenesis Therapeutics, Inc. | U.S.A. | 100 | % | |||
Industrias Quimicas Falcon de Mexico, SA de CV | Mexico | 100 | % | |||
Reddy Holding GmbH | Germany | 100 | %(7) | |||
Lacock Holdings Limited | Cyprus | 100 | % | |||
betapharm Arzneimittel GmbH | Germany | 100 | %(8) | |||
beta Healthcare Solutions GmbH | Germany | 100 | %(8) | |||
beta institut fur sozialmedizinische Forschung und Entwicklung GmbH | Germany | 100 | %(8) | |||
Reddy Pharma Iberia SA | Spain | 100 | % | |||
Reddy Pharma Italia SPA | Italy | 100 | %(7) | |||
Dr. Reddy’s Laboratories (Australia) Pty Ltd. | Australia | 100 | % | |||
Dr. Reddy’s Laboratories SA | Switzerland | 100 | % | |||
Eurobridge Consulting B.V. | Netherlands | 100 | %(1) | |||
OOO DRS LLC | Russia | 100 | %(9) | |||
Aurigene Discovery Technologies(Malaysia ) Sdn, Bhd | Malaysia | 100 | %(3) | |||
Dr. Reddy’s New Zealand Limited (formerly Affordable Healthcare Limited) | New Zealand | 100 | %(10) | |||
Dr. Reddy’s Laboratories Ilac Ticaret Limited | Turkey | 100 | % | |||
Dr. Reddy’s SRL (formerly Jet Generici SRL) | Italy | 100 | %(11) | |||
Chirotech Technology Limited | United Kingdom | 100 | %(5) | |||
Dr. Reddy’s Laboratories Louisiana LLC | U.S.A. | 100 | %(6) | |||
Dr. Reddy’s Pharma SEZ Limited | India | 100 | % | |||
Dr. Reddy’s Laboratories International SA | Switzerland | 100 | %(8) | |||
Idea2Enterprises (India) Pvt. Limited | India | 100 | % | |||
Dr. Reddy’s Laboratories Romania SRL | Romania | 100 | %(10) | |||
I-Ven Pharma Capital Limited | India | 100 | %(13) | |||
Dr. Reddy’s Venezuela, C.A | Venezula | 100 | %(13) | |||
Dr. Reddy’s Laboratories Tennessee, LLC | U.S.A | 100 | %(6) |
(1) | Indirectly owned through Reddy Antilles N.V. | |
(2) | Subsidiary under liquidation. |
(3) | Indirectly owned through Aurigene Discovery Technologies Limited. | |
(4) | Kunshan Rotam Reddy Pharmaceutical Co. Limited is a subsidiary as we hold a 51.33% stake; however, we account for this investment by the equity method and do not consolidate it in our financial statements. | |
(5) | Indirectly owned through Dr. Reddy’s Laboratories (EU) Limited. | |
(6) | Indirectly owned through Dr. Reddy’s Laboratories, Inc. | |
(7) | Indirectly owned through Lacock Holdings Limited. | |
(8) | Indirectly owned through Reddy Holding GmbH. | |
(9) | Indirectly owned through Eurobridge Consulting B.V. | |
(10) | Indirectly owned through Dr. Reddy’s Laboratories SA. | |
(11) | Indirectly owned through Reddy Pharma Italia SPA | |
(12) | We acquired the 40% non-controlling interest in August 2010. | |
(13) | Indirectly owned through DRL Investments Limited |
Macred India Private Limited, India was our wholly owned subsidiary until July 19, 2010, at which time we sold an 80% controlling interest in the entity and retained a 20% non-controlling interest.